Last edition
News about "AnaptysBio "
TESARO Provides Update on AnaptysBio Litigation
TESARO Inc., part of GlaxoSmithKline plc, provides an update on litigation with AnaptysBio Inc., reaffirming its declaratory judgment claim and intent to pursue the case at trial.
AnaptysBio | 28/04/2026 | By News Bureau
Vanda’s imsidolimab moves closer to approval as the FDA accepts its BLA for generalised pustular psoriasis, a rare and life-threatening inflammatory skin disorder.
AnaptysBio | 02/03/2026 | By News Bureau | 135
Vanda and Anaptys to Develop and Commercialize Imsidolimab
GPP is a rare skin disorder often caused by mutations in the IL36RN gene that codes for a regulatory protein that balances the activity of the proinflammatory IL-36 family of cytokines.
AnaptysBio | 04/02/2025 | By Aishwarya | 546
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy